Comparative evaluation of itopride and domperidone in gastroesophageal reflux disease

Kumar, Rahul; Sharma, Priyamvada

doi:10.5455/2319-2003.ijbcp20140604

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained in a prospective randomised trial of itopride, 150 mg/day, with lansoprazole, 30 mg, achieving a complete resolution of symptoms after 12 weeks of treatment [ 31 ] or with rabeprazole, 20 mg, noting an improvement after 6 weeks [ 32 ]. Reports from comparative efficacy studies of itopride and domperidone with PPIs (20 mg rabeprazole for 8 weeks and esomeprazole 40 mg for 4 weeks) are also available in the literature, not only highlighting the superiority of itopride over domperidone, but also confirming the high safety and efficacy of itopride in combination therapies [ 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease

Wasko-Czopnik,

Wiatrak

2024

View full text Add to dashboard Cite

Introduction The primary objective was to demonstrate the efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor (PPI) in the treatment of gastroesophageal reflux disease. Aim Reflux disease affects the largest percentage of the population worldwide, symptoms overlap with many other conditions which hamper diagnostic and therapy presenting challenges in treating patients and prompting an intensive search for new, more effective therapeutic regimens. Material and methods A retrospective study was undertaken with 140 enrolled patients with reflux disease, confirmed by 24-hour pH impedance previously treated with PPIs without any significant improvement. Itopride was added to the PPI therapy in a dose of 150 mg/day, after which the severity of reflux disease symptoms was reassessed. Results The greatest improvement after the combined treatment ( p < 0.001) was experienced in the context of heartburn, nausea and laryngopharyngeal symptoms. There was also a high percentage of statistically significant ( p < 0.01) improvement in burning in the oesophagus and stomach and regarding postprandial fullness, gastric retention and swallowing disorders. No adverse effects were noted. Conclusions The presented study clearly demonstrates that in patients ineffectively treated with PPIs, the addition of itopride to the therapy for 8 weeks without changing the PPI dose, significantly improves the efficacy of treatment of reflux disease and thus shortens the need for medication usage and reduces the costs of therapy, potential side effects of PPI, improves the patient’s quality of life and decreases the frequency of medical appointments.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease

Wasko-Czopnik,

Wiatrak

2024

View full text Add to dashboard Cite

show abstract

“…In a study by Choi et al, itopride decreased the total symptoms after treatment and they found 300 mg of itopride to be more effective than 150 mg. No adverse effects were reported in their study. Rahul Kumar et al 15 observed combination of itopride and rabeprazole had significantly better results, both symptomatically and endoscopically in comparison to the combination of domperidone and rabeprazole. In a study by Corazza et al, 16 (n=1298) on levosulpiride in functional dyspepsia, levosulpiride was found significantly (p<0.01) superior to domperidone, metoclopramide and placebo as it gave better improvement clinically and improved the symptoms of postprandial bloating, epigastric pain, heartburn also.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Safety and Efficacy of Levosulpiride and Itopride in Treatment of Gastroesophageal Reflux Disease

Hassan¹,

Hassan²

2017

jebmh

View full text Add to dashboard Cite

BACKGROUNDGastroesophageal Reflux Disease (GERD) is a common condition caused by reflux of the liquid acidic contents of the stomach into the oesophagus. Prokinetic medications can be used to treat or control the disease. Such medications can have mild-toserious adverse effects. Levosulpiride and itopride are two such medications, which are used for treating GERD.The aim of the study is to assess the safety and efficacy of levosulpiride and itopride in the management of GERD and to study the side effects and treatment outcome. MATERIALS AND METHODSA total 210 patients aged 18 to 90 years, 99 males and 111 females (male:female ratio of 1:1.1) with reflux oesophagitis were divided into three groups and an endoscopy test was done before starting treatment. The control group received rabeprazole and the two test groups received levosulpiride and itopride. Clinical adverse events were recorded at the end of week 1 and week 2. Following treatment, relief of symptoms was assessed at the end of 2 weeks. RESULTSThere were total 210 patients (99 males and 111 females). The male-to-female ratio was 1:1.1. GERD was more common in the 31-50 year age group. Most common symptoms were of dyspepsia, regurgitation, vomiting and heartburn. Improvement of symptoms during the treatment was seen in 53% levosulpiride and 41% itopride patients, respectively. The main adverse effects were abdominal pain and nausea. The percentage of nausea was high with itopride than levosulpiride. CONCLUSIONGastroesophageal reflux disease is a common problem frequently seen in both genders and in younger people. Symptomatic relief and endoscopic recovery is early with levosulpiride than itopride. Levosulpiride gives better quality of life earlier in the treatment than itopride and has lesser side effects and better healing outcome. KEYWORDSGastroesophageal Reflux Disease, Levosulpiride, Itopride. HOW TO CITE THIS ARTICLE:Hassan SI, Hassan SMA. Comparison of safety and efficacy of levosulpiride and itopride in treatment of gastroesophageal reflux disease. J. Evid. Based Med.

show abstract

Comparative evaluation of itopride and domperidone in gastroesophageal reflux disease

Cited by 2 publications

References 5 publications

The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease

The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease

Comparison of Safety and Efficacy of Levosulpiride and Itopride in Treatment of Gastroesophageal Reflux Disease

Contact Info

Product

Resources

About